10x Genomics (TXG) CEO sells 10,486 shares under 10b5-1 plan

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) reported that its Chief Executive Officer, Serge Saxonov, sold a total of 10,486 shares of Class A Common Stock on August 26, 2026. The sales, executed as open-market or private transactions, were carried out pursuant to a Rule 10b5-1 trading plan adopted on November 29, 2025 and occurred in multiple trades with weighted average prices between approximately $62.53 and $64.99. The filing also notes indirect holdings of Class A shares in three trusts—the Andromeda Trust, the Y/S Descendants' Trust, and the Y/S Pot Trust—for which Saxonov serves as trustee.

Insider Trade Summary 10b5-1

Net Seller: 10,486 shares

Net Sell 6 txns

Insider Saxonov Serge

Role Chief Executive Officer

Sold 10,486 shs ($668K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1, F2	3,500	$63.0229	$221K
Sale	Class A Common Stock F1, F3	6,494	$63.9768	$415K
Sale	Class A Common Stock F1, F4	492	$64.7465	$32K
holding	Class A Common Stock F5	--	--	--
holding	Class A Common Stock F6	--	--	--
holding	Class A Common Stock F7	--	--	--

Holdings After Transaction: Class A Common Stock — 1,075,349 shares (Direct); Class A Common Stock — 284,921 shares (Indirect, See footnote)

Footnotes (7)

1. F1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
2. F2. This transaction was executed in multiple trades at prices ranging from $62.53 to $63.50, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. F3. This transaction was executed in multiple trades at prices ranging from $63.56 to $64.54, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. F4. This transaction was executed in multiple trades at prices ranging from $64.59 to $64.99, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
5. F5. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
6. F6. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
7. F7. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

Key Figures

Shares sold (block 1): 3,500 shares of Class A Common Stock Shares sold (block 2): 6,494 shares of Class A Common Stock Shares sold (block 3): 492 shares of Class A Common Stock +5 more

8 metrics

Shares sold (block 1) 3,500 shares of Class A Common Stock Sale on August 26, 2026 at a weighted average price of $63.0229 per share

Shares sold (block 2) 6,494 shares of Class A Common Stock Sale on August 26, 2026 at a weighted average price of $63.9768 per share

Shares sold (block 3) 492 shares of Class A Common Stock Sale on August 26, 2026 at a weighted average price of $64.7465 per share

Total shares sold 10,486 shares of Class A Common Stock Aggregate net-sell volume reported in transaction summary

Rule 10b5-1 trading plan adoption date November 29, 2025 Date the CEO’s trading plan referenced for these sales was adopted

Price range (block 1 trades) $62.53 to $63.50 per share Range of prices for trades comprising the first reported sale block

Price range (block 2 trades) $63.56 to $64.54 per share Range of prices for trades comprising the second reported sale block

Price range (block 3 trades) $64.59 to $64.99 per share Range of prices for trades comprising the third reported sale block

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, indirect ownership, Class A Common Stock, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

indirect ownership financial

"The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee"

Class A Common Stock financial

"security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

net-sell financial

"transactionSummary reports netBuySellDirection as net-sell"

FAQ

What insider transaction did TXG CEO Serge Saxonov report on this Form 4?

Serge Saxonov reported selling 10,486 shares of 10x Genomics, Inc. Class A Common Stock on August 26, 2026, in open-market or private transactions, according to the Form 4.

At what prices were the TXG shares sold by the CEO on August 26, 2026?

The reported sales were executed in multiple trades at prices ranging from $62.53 to $64.99 per share, with the Form 4 presenting weighted average sale prices of $63.0229, $63.9768, and $64.7465 for the respective transaction blocks.

How many TXG shares did the CEO sell in each transaction block?

On August 26, 2026, the CEO sold 3,500 shares at a weighted average price of $63.0229, 6,494 shares at $63.9768, and 492 shares at $64.7465, for a total of 10,486 shares sold.

Was the TXG CEO’s August 26, 2026 stock sale under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were effected pursuant to the reporting person’s Rule 10b5-1 trading plan, which was adopted on November 29, 2025.

Does the TXG CEO hold shares indirectly through trusts?

Yes. The Form 4 states that Class A Common Stock is held by the Andromeda Trust, the Y/S Descendants' Trust, and the Y/S Pot Trust, for which Serge Saxonov serves as trustee, reflecting indirect ownership.

How many TXG shares in total were reported as sold on this Form 4?

The transaction summary reports that 10,486 shares of 10x Genomics, Inc. Class A Common Stock were sold, with a net buy/sell direction classified as net-sell.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/28/2026 - 07:23 PM Accepted by SEC EDGAR 08/28/2026 - 07:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saxonov Serge

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CALIFORNIA 94588

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/26/2026		S(1)		3,500	D	$63.0229(2)	1,082,335	D
Class A Common Stock	08/26/2026		S(1)		6,494	D	$63.9768(3)	1,075,841	D
Class A Common Stock	08/26/2026		S(1)		492	D	$64.7465(4)	1,075,349	D
Class A Common Stock								27	I	See footnote(5)
Class A Common Stock								213,250	I	See footnote(6)
Class A Common Stock								71,644	I	See footnote(7)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.

2. This transaction was executed in multiple trades at prices ranging from $62.53 to $63.50, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. This transaction was executed in multiple trades at prices ranging from $63.56 to $64.54, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. This transaction was executed in multiple trades at prices ranging from $64.59 to $64.99, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

5. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

6. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

7. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

	/s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)